Variant Pharmaceuticals, Inc.
2200 N Commerce Pkwy
2 articles with Variant Pharmaceuticals, Inc.
Reflects the versatility required to be on the forefront of innovation to meet unmet medical needs
Variant Pharmaceuticals Expands Development Focus Into $60+ Billion Anti-inflammatory Market with Worldwide License to Novel Inflammasome Inhibitor
Novel Inflammasome inhibitor, which uniquely targets ASC, represents a differentiated approach to block abnormal immune responses driving the onset of inflammatory diseases